GlassScriptPhysician profile
Donald C Townsend
NPI 1164447660
$2,811.30
in general payments reported to CMS, 2019-2025
17 companies · $2,401 in 2025
The $2,401 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $297 · 2020: $41.15 · 2022: $72.56 · 2025: $2,401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,401.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,400.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noctrix Health, INC. | $2,400.83 | 2025 | Nidra |
| Novartis Pharmaceuticals Corporation | $96.70 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $72.56 | 2022 | |
| Genentech USA, INC. | $45.78 | 2019 | |
| Celgene Corporation | $21.23 | 2019 | |
| Abbvie INC. | $19.04 | 2019 | |
| Incyte Corporation | $17.31 | 2019 | |
| Eisai INC. | $17.01 | 2020 | |
| Amgen INC. | $15.45 | 2019 | |
| Daiichi Sankyo INC. | $15.07 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $14.18 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.97 | 2019 | |
| Eusa Pharma (US) LLC | $13.14 | 2019 | |
| Lilly USA, LLC | $12.90 | 2019 | |
| Exelixis INC. | $12.82 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $11.85 | 2019 | |
| Puma Biotechnology, INC. | $11.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Townsend listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.